BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Antitope Announces Research Collaboration with Ablynx


8/25/2010 10:03:20 AM

25 August 2010 - Antitope Ltd. of Cambridge UK (“Antitope”) today announced a research collaboration with Ablynx NV of Ghent, Belgium ("Ablynx") whereby Antitope will apply its proprietary EpiScreenTM technology to profile a series of Nanobodies® developed by Ablynx for possible T cell epitopes.

“We are delighted to be working with Ablynx whose Nanobody-based therapeutic research programmes represent exciting new opportunities in a range of major disease areas” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, "We look forward to applying the EpiScreenTM technology to enable Ablynx to select Nanobodies with the lowest potential for immunogenicity."

Dr Hilde Revets, Senior Research Fellow of Ablynx added: “We are looking forward to our collaboration with Antitope. This study will help to further characterise our Nanobody platform.”

About Antitope

Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology provides for preclinical analysis of the immunogenicity potential of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

For further information on Antitope visit; http://www.antitope.co.uk or contact: Dr. Neil Butt Business Development Director, Antitope Ltd. Tel: +44 (0)1223 496190

Nanobody is a registered trademark of Ablynx NV



Read at BioSpace.com

Antitope
Ablynx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES